You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 14, 2025

Drugs in MeSH Category Anti-Ulcer Agents


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva CIMETIDINE cimetidine TABLET;ORAL 074463-001 May 17, 1994 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Sandoz CIMETIDINE cimetidine TABLET;ORAL 075122-002 Jun 19, 1998 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Ivax Sub Teva Pharms CIMETIDINE cimetidine TABLET;ORAL 074424-003 Jul 28, 1995 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Perrigo R And D FAMOTIDINE famotidine TABLET;ORAL 077351-001 Sep 25, 2006 OTC No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Takeda Pharms Usa DEXILANT dexlansoprazole CAPSULE, DELAYED RELEASE;ORAL 022287-002 Jan 30, 2009 AB RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Glaxosmithkline TAGAMET cimetidine TABLET;ORAL 017920-003 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Anti-Ulcer Agents Market Analysis and Financial Projection

The global anti-ulcer drug market is undergoing significant transformation, driven by therapeutic advancements and evolving patent dynamics. Here's a comprehensive analysis of current trends and future trajectories:


Market Dynamics

Growth Drivers

  • Prevalence Surge: The market (valued at $42.6B in 2025 [5]) is propelled by rising gastrointestinal disorders, stress-related ulcers, and an aging population, with a projected 4.9–9.3% CAGR through 2032 [1][15]. Proton pump inhibitors (PPIs) and H2-receptor antagonists dominate due to efficacy in acid suppression [1][14].
  • Innovative Therapies: Pipeline drugs like Takeda’s Vonoprazan fumarate (P-CAB class, Phase III) [3] and combo therapies (e.g., Talicia for H. pylori [3]) are reshaping treatment protocols.
  • Regional Shifts: Region Market Share (2025) Key Factors
    North America 30% [1] High NSAID usage, advanced healthcare
    Asia-Pacific 20% [1] Rising healthcare access, urbanization
    Europe 25% [1] Strong generics sector, regulatory frameworks

Challenges

  • Side Effects: Long-term PPI use links to magnesium deficiency and increased infection risks [3][14].
  • Cost Pressures: Patent expirations (e.g., Prevacid generics) intensify price competition [6].

Key Players: AstraZeneca (PPIs), Pfizer, and Takeda lead innovation, with AstraZeneca’s gastroenterology segment contributing to its $37B revenue [1]. Emerging markets see local manufacturers gaining traction through cost-effective generics [7].


Patent Landscape

Innovation Trends

  • Novel Compounds: Recent patents include quassinoid derivatives (EP0206112A1 [2]) and H. pylori-targeting formulations (King Saud University’s USPTO 8933267 [8]).
  • Combination Therapies: 65% of new patents focus on antibiotic-PPI combos to enhance H. pylori eradication [10].

Secondary Patent Dominance

  • Anti-ulcer drugs exhibit a 1:4 primary-to-secondary patent ratio [11], extending monopolies through formulation tweaks (e.g., extended-release PPIs) and delivery methods.
2025 Patent Cliffs Drug Company Impact
Stelara Johnson & Johnson Biosimilars to cut Crohn’s treatment costs [13]
Jardiance Boehringer Ingelheim Generic SGLT2 inhibitors challenge diabetes market [13]

Litigation Risks: Non-steroidal anti-inflammatory drug (NSAID) formulations face challenges as 28% of patents target NSAID-induced ulcer prevention [12].


Future Outlook

  • Personalized Medicine: CRISPR-based H. pylori detection and microbiome modulators are under exploration [15].
  • Biosimilar Surge: Post-2025, biosimilars for biologics like Stelara will reduce treatment costs by ~40% [13].
  • Digital Integration: AI-driven adherence tools (e.g., smart pillboxes) aim to address poor compliance in chronic ulcer management [1].

"The shift toward combo therapies and secondary patents reflects industry efforts to balance innovation with lifecycle management." – Market Analysis [1][11].

As generics and biosimilars gain ground, manufacturers must prioritize R&D in underserved areas (e.g., pediatric formulations) and emerging markets to sustain growth. Regulatory focus on drug safety (e.g., FDA’s 2024 PPI labeling mandates [14]) will further shape market entry strategies.

References

  1. https://github.com/zdybelzinn/Market-Research-Report-List-1/blob/main/anti-ulcer-drug-market.md
  2. https://patents.google.com/patent/EP0206112A1/en
  3. https://www.fortunebusinessinsights.com/peptic-ulcer-drugs-market-103483
  4. https://meshb.nlm.nih.gov/record/ui?ui=D000897
  5. https://www.persistencemarketresearch.com/market-research/peptic-ulcer-drugs-market.asp
  6. https://aem-prod.oklahoma.gov/content/dam/ok/en/okhca/docs/about/boards-and-committees/dur/2024/june/06122024%20DUR%20Packet.pdf
  7. https://www.datamintelligence.com/research-report/antiulcerant-drugs-market
  8. https://patents.justia.com/patent/8933267
  9. https://pharsight.greyb.com/collections/drugs-opening-to-patent-challenges-in-2025
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC11086278/
  11. https://journals.plos.org/plosone/article?id=info%3Adoi%2F10.1371%2Fjournal.pone.0124257
  12. https://pubmed.ncbi.nlm.nih.gov/33843400/
  13. https://biopharmaapac.com/analysis/60/5727/25-high-value-drugs-losing-patent-protection-in-2025-what-it-means-for-healthcare.html
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC10538946/
  15. https://datahorizzonresearch.com/anti-peptic-ulcer-drugs-market-4408
Last updated: 2025-03-27

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.